戻る
Incyte Corp (INCY)価格
INCY 株価推移チャート
INCY 財務
Incyte Corp
$106.21
0.92%
$0.96
終値： Jan 16, 16:00:00 GMT-5
$106.88
0.63%
$0.67
アフターマーケット：Jan 16, 20:00:00 GMT-5
B
最終スコア
主要データ
前終値
$105.24
始値
$105.55
当日レンジ
$104.83 - $108.58
52週レンジ
$53.56 - $112.29
取引高
1.6M
平均取引高
2.3M
1株当たり利益(TTM)
5.91
配当利回り
--
時価総額
$20.9B
INCYとは何ですか？
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,617 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.